標(biāo)題: Titlebook: Making Medicines in Africa; The Political Econom Maureen Mackintosh (Professor of Economics),Geoffr Book‘‘‘‘‘‘‘‘ 2016 The Editor(s) (if app [打印本頁(yè)] 作者: Aggrief 時(shí)間: 2025-3-21 17:50
書目名稱Making Medicines in Africa影響因子(影響力)
書目名稱Making Medicines in Africa影響因子(影響力)學(xué)科排名
書目名稱Making Medicines in Africa網(wǎng)絡(luò)公開度
書目名稱Making Medicines in Africa網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Making Medicines in Africa被引頻次
書目名稱Making Medicines in Africa被引頻次學(xué)科排名
書目名稱Making Medicines in Africa年度引用
書目名稱Making Medicines in Africa年度引用學(xué)科排名
書目名稱Making Medicines in Africa讀者反饋
書目名稱Making Medicines in Africa讀者反饋學(xué)科排名
作者: bile648 時(shí)間: 2025-3-21 23:42
Finance and Incentives to Support the Development of National Pharmaceutical Industriesn, rely on the building up of appropriate financial capabilities within firms and financial institutions as well as within governments. This chapter innovatively traces the interconnections between micro-level financial capabilities and national government policy competences in the design and effect作者: allergen 時(shí)間: 2025-3-22 04:08 作者: Keratectomy 時(shí)間: 2025-3-22 06:21
2662-2483 urces to tackle its populations‘ needs and demands.?.? .Research for this book has been selected as one of the 20 best examples of the impact of UK res978-1-137-57133-5978-1-137-54647-0Series ISSN 2662-2483 Series E-ISSN 2662-2491 作者: callous 時(shí)間: 2025-3-22 10:36 作者: Annotate 時(shí)間: 2025-3-22 16:48
Paula Tibandebage,Samuel Wangwe,Maureen Mackintosh,Phares G. M. Mujinja作者: 黃油沒有 時(shí)間: 2025-3-22 17:04 作者: 急性 時(shí)間: 2025-3-22 22:41
Joseph Fortunak,Skhumbuzo Ngozwana,Tsige Gebre-Mariam,Tiffany Ellison,Paul Watts,Martins Emeje,Frede作者: GLARE 時(shí)間: 2025-3-23 03:14
Maureen Mackintosh,Paula Tibandebage,Joan Kariuki Kungu,Mercy Karimi Njeru,Caroline Israel作者: orient 時(shí)間: 2025-3-23 08:40
Erika Arag?o,Jane Mary Guimar?es,Sebasti?o Loureiro作者: Androgen 時(shí)間: 2025-3-23 10:51
Geoffrey Banda,Julius Mugwagwa,Dinar Kale,Margareth Ndomondo-Sigonda作者: superfluous 時(shí)間: 2025-3-23 15:47 作者: obstruct 時(shí)間: 2025-3-23 20:17
Theo Papaioannou,Andrew Watkins,Julius Mugwagwa,Dinar Kale作者: 溺愛 時(shí)間: 2025-3-24 01:34
Sudip Chaudhuriith the same device volume. The peak value for the phase angle shift is also larger in triangular bimorphs, indicating a larger dielectric loss at the median of the resonance and anti-resonance frequencies; implying that the devices here would be more compliant, i.e. provide a wider resonance freque作者: JEER 時(shí)間: 2025-3-24 02:29
Introduction: African Industrial Development, Values and Health Careare rooted in the needs of a subcontinent with the worst health status in the world. The central argument of this book is that industrial development in pharmaceuticals and the capabilities it generates are necessary elements in African initiatives to tackle these acute health care needs. A successf作者: excursion 時(shí)間: 2025-3-24 07:48
Making Medicines in Africa: An Historical Political Economy Overviewy with a long history dating back at least to the 1930s. Data for the industry on the subcontinent are fragmented and incomplete (Berger et al., 2009; UNIDO, 2010a; 2010b; 2011a; 2011b), and this chapter and this book contribute to building a coherent historical picture and evidence base. This chapt作者: 小平面 時(shí)間: 2025-3-24 12:26 作者: Flu表流動(dòng) 時(shí)間: 2025-3-24 16:28
Pharmaceutical Manufacturing Decline in Tanzania: How Possible Is a Turnaround to Growth?dence industrial history. By 2004–05, the sector was estimated to be producing pharmaceuticals worth US$32.5 million, supplying around 30% of the local market and exporting about 10% of local production (MoHSW, 2006). The subsequent rise and decline of the sector is analysed in this chapter, locatin作者: Immunotherapy 時(shí)間: 2025-3-24 20:50
Bringing Industrial and Health Policies Closer: Reviving Pharmaceutical Production in Ethiopiale producer of medicines throughout the military regime (1974–91). Following the regime change in 1991, several manufacturing plants were established during the period referred to as the ‘boom and crash’ period, since, for reasons described below, some of the new companies were not successful. To re作者: attenuate 時(shí)間: 2025-3-25 01:26 作者: demote 時(shí)間: 2025-3-25 06:26 作者: 哪有黃油 時(shí)間: 2025-3-25 10:34
Raising the Technological Level: The Scope for API, Excipients, and Biologicals Manufacture in Africin Africa — a hitherto nascent industry. It also discusses African drug development and manufacturing through the standardized use of ‘reverse pharmacology’ to bring new treatments for neglected diseases to the point of regulatory approvals. Currently there is very modest production of APIs on the A作者: CRAMP 時(shí)間: 2025-3-25 11:57
Health Systems as Industrial Policy: Building Collaborative Capabilities in the Tanzanian and Kenyancy for manufacturers of medicines and medical supplies is not new. In a European context, Thomas (1994) argued that post-1945 UK health care pricing and regulation policies drove a shift to global competitiveness in the locally based pharmaceutical industry, while French post-war health policy did n作者: Somber 時(shí)間: 2025-3-25 18:01 作者: 有惡意 時(shí)間: 2025-3-25 22:40
Healthy Industries and Unhealthy Populations: Lessons from Indian Problem-Solvingy has had three defining policy environments running from 1950 to 2000, the last of which is arguably still ongoing. These three environments are distinct . environments, in which the range of market instruments used has been notable and the public gains to which they have been put have been notewor作者: 散步 時(shí)間: 2025-3-26 02:25
Policies to Control Prices of Medicines: Does the South African Experience Have Lessons for Other Af. One of the key constraints is the high prices of medicines. In the private sector, wholesale and retail mark-ups have been found to range from 2% to 380% and from 10% to 552%, respectively (Cameron et al., 2011). A later study found wholesaler mark-ups between 25% and 50% (IMS Health, 2014a; 2014b作者: Robust 時(shí)間: 2025-3-26 08:03
Pharmaceutical Standards in Africa: The Road to Improvement and Their Role in Technological Capabili sector, regulators, technical experts, procurement agencies, health system actors and policy makers to mean different things. There is a dearth of systematic studies that address what standards are, their classification and the logic behind their set-up and operation, and this has contributed to a 作者: 排出 時(shí)間: 2025-3-26 10:49
Innovative Procurement for Health and Industrial Developmentpolitics and political economy of the two systems. A key tool for building and sustaining health-industry relationships, as Smita Srinivas observes above and as some Part I chapters also emphasized, is procurement. Yet procurement remains under-researched and over-simplified as a technical, linear, 作者: 處理 時(shí)間: 2025-3-26 16:15
Industry Associations and the Changing Politics of Making Medicines in South Africarently political. As such, the relational and political interactions between industry and government are key to shaping regulatory environments that either promote or constrain an industry’s ability to collectively learn, innovate and grow (Malerba, 2002). Often critical to the governing of these re作者: 是剝皮 時(shí)間: 2025-3-26 20:01
Finance and Incentives to Support the Development of National Pharmaceutical Industries and improved public health. This final chapter begins by identifying the striking convergence of thought and initiative that has recently been generated across continental African representative bodies, international agencies and national governments. We outline this emergent consensus and then exa作者: 名次后綴 時(shí)間: 2025-3-26 23:47
Sudip Chaudhuri that tapering the geometry into triangular shapes provides a constant strain distribution over the surface of cantilevered bimorphs, unlike conventional rectangular geometries with a large tip mass. This enhances the k.?electromechanical coupling coefficients in the devices, an aspect which is stud作者: 打火石 時(shí)間: 2025-3-27 03:38 作者: 熱心 時(shí)間: 2025-3-27 06:32
Health Systems as Industrial Policy: Building Collaborative Capabilities in the Tanzanian and Kenyanot. Reich (1990) has argued that Japanese success in pharmaceuticals was nurtured, not by the MITI’s industrial policy, but mainly by government regulation and funding of the health sector and manipulation of pharmaceutical pricing.作者: MAIZE 時(shí)間: 2025-3-27 10:53
The Dissemination of Local Health Innovations: Political Economy Issues in Brazilhe pharmaceutical sector. Although more than 25 years have passed since Unified Health System (. : SUS) was established, and much progress has been made, a great many challenges remain. This chapter focuses particularly on those related to access to health technologies.作者: refine 時(shí)間: 2025-3-27 14:30
Policies to Control Prices of Medicines: Does the South African Experience Have Lessons for Other Af), and retail mark-ups between 25% and 500% (Rosen and Rickwood, 2014). Local manufacturers and importers alike have expressed concern over the high mark-ups in the distribution chain, as the exorbitant prices are believed to limit patients’ access and sales.作者: Customary 時(shí)間: 2025-3-27 20:45
Pharmaceutical Standards in Africa: The Road to Improvement and Their Role in Technological Capabilihuge asymmetry in understanding. The socio-economic, technical and political issues and how they have an impact on local production and industry development, including their effects on access to markets, have also not been systematically explored.作者: TRAWL 時(shí)間: 2025-3-27 22:40
Innovative Procurement for Health and Industrial Developmentove and as some Part I chapters also emphasized, is procurement. Yet procurement remains under-researched and over-simplified as a technical, linear, ordering and delivery process (see Chapter 8), rather than an exercise in deepening and strengthening the domestic economy through market and non-market relationships building.作者: antecedence 時(shí)間: 2025-3-28 02:24
Introduction: African Industrial Development, Values and Health Cares people without access to competent care. However, without the technological, industrial, intellectual, organizational and research-related capabilities associated with competent pharmaceutical production, the African subcontinent cannot generate the resources to tackle the needs and demands of its population.作者: Restenosis 時(shí)間: 2025-3-28 07:58 作者: podiatrist 時(shí)間: 2025-3-28 13:41
Pharmaceutical Manufacturing Decline in Tanzania: How Possible Is a Turnaround to Growth?lization of firms’ domestic and regional markets. Finally, the chapter examines the ‘turnaround’ challenge facing the local industry. Concerned policy makers are aware, as the above quotation shows, of the health sector insecurity inherent in complete reliance on medicines imports.作者: 多節(jié) 時(shí)間: 2025-3-28 14:43 作者: Devastate 時(shí)間: 2025-3-28 20:56
Raising the Technological Level: The Scope for API, Excipients, and Biologicals Manufacture in Africges.. Generic producers in India and China supply nearly all of the APIs used in African pharmaceutical manufacturing. Most African companies cannot afford the heavy investment and research and development activities required for API production.作者: 晚間 時(shí)間: 2025-3-29 02:02
Bringing Industrial and Health Policies Closer: Reviving Pharmaceutical Production in Ethiopia private initiative to engage in industrial investment. Joint ventures that were realized have not only contributed to the pharmaceutical industry; they also effectively transferred skill and technology.作者: chlorosis 時(shí)間: 2025-3-29 03:45 作者: Apoptosis 時(shí)間: 2025-3-29 07:30
Maureen Mackintosh (Professor of Economics),GeoffrEditors and authors with a strong African and more broadly Southern presence.Groundbreaking analysis of the pharmaceutical industry in Africa作者: 花費(fèi) 時(shí)間: 2025-3-29 13:35 作者: Osmosis 時(shí)間: 2025-3-29 17:26 作者: GULLY 時(shí)間: 2025-3-29 23:39
South-South Collaboration in Pharmaceuticals: Manufacturing Anti-retroviral Medicines in Mozambiquein Mozambique, to be entirely owned by the national government. The project — widely known as the Brazil-Mozambican anti-retro-viral factory because of its commitment to produce AIDS drugs — still represents the single most expensive and eye-catching project of Brazil’s South-South cooperation programme in the health sector.作者: Flounder 時(shí)間: 2025-3-30 02:50 作者: indifferent 時(shí)間: 2025-3-30 04:56 作者: 武器 時(shí)間: 2025-3-30 10:43 作者: resistant 時(shí)間: 2025-3-30 12:39 作者: orthopedist 時(shí)間: 2025-3-30 18:58
10樓作者: 博愛家 時(shí)間: 2025-3-30 21:14
10樓作者: conquer 時(shí)間: 2025-3-31 01:58
10樓作者: 富足女人 時(shí)間: 2025-3-31 06:11
10樓
